A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Latest Information Update: 01 Dec 2025
At a glance
- Drugs Dapagliflozin formate (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Dong-A ST
Most Recent Events
- 01 Dec 2025 New trial record